Abstract
Peritoneal dialysis (PD) is a life-sustaining kidney replacement therapy, for the increasing number of people suffering permanent kidney failure across all age groups worldwide. Although PD potentially offers socio-economic and performance benefits over haemodialysis (HD), both treatments severely accelerate complications of chronic kidney disease (CKD), in particular atherosclerotic disease progression that worsen outcomes when compared with non-dialysis patients 1. Improved understanding of the underlying molecular pathogenic mechanisms should help in the design of interventions that improve outcomes 2.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
